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CObjectives: Medical innovation in developed countries has been linked
to burden of disease, with more innovation in areas representing
greater investment return. This study used horizon scanning or early
awareness and alert activity as a novel measure of innovation to deter-
mine whether new and emerging health technologies reported by in-
ternational horizon scanning agencies reflected diseases constituting
the greatest burden. Methods: This was a retrospective observational
study of the 20 member agencies of EuroScan (the International Infor-
mation Network on New and Emerging Health Technologies), repre-
senting 17 developed countries. Burden of disease was defined as
disability-adjusted life-years, taken from the 2004 World Health Or-
ganization Global Burden of Disease estimates. This analysis focused
on 102 specific diseases within 21 broader groups. Horizon scanning
output was measured as the number of technologies reported by Euro-
Scan member agencies between 2000 and 2009. Results: At best there
was a weak association between innovation and burden of disease. An O
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oi:10.1016/j.jval.2011.11.034pparent high-level association was dependent on just three high-
revalence disease groups: malignant neoplasms, neuropsychiatric
onditions, and cardiovascular disease. Disaggregating broader groups
nto specific diseases further weakened the association. Innovation is
isproportionately strong in cancer andnonischemic heart disease and
isproportionately weak in mental health. Conclusions: Innovations
eported by early awareness and alert systems do not always reflect
onditions accounting for the highest morbidity and mortality. The
esults do not support previous reports of a positive relationship be-
ween burden of disease and innovation, but accord with evidence of
otable discrepancies among key groups. Factors other than disease
urden drive innovation.
eywords: burden of illness, epidemiology, health services, innovation.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
In developed countries the main disease burden is from noncom-
municable conditions, most notably cardiovascular disease, can-
cer, and neuropsychiatric conditions [1,2]. The development of
new health technologies might be expected to focus on diseases
with high morbidity and mortality, to reflect areas of greater bur-
den. However, because the innovation process is long, costly [3,4],
ften unsuccessful, and largely commercially driven, innovation
ypically reflects all the factors influencing investment return, of
hich burden of disease is just one [5–7].
The existing evidence of a positive relationship between bur-
en of disease and innovation is based mainly on input measures
f innovation such as public and charitable research and develop-
ent (R&D) funding [8,9]. This association may be a reflection of
ealth-care policy, in particular calls to address the burden of spe-
ific diseases including cancer and dementia [10–13]. There are
oncerns, however, that some disease areas are underfunded. A
ecent report by the UK Clinical Research Collaboration found that
lthough research spending in the United Kingdom broadly corre-
* Address correspondence to: Orsolina I. Martino, National Horizo
aston, Birmingham B15 2SP, UK.
E-mail: o.i.martino@bham.ac.uk.
098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.sponded to burden of disease, cancer attracted a disproportion-
ately high level of funding whereas blood system disorders, car-
diovascular diseases, and stroke received comparatively little
funding [9]. Furthermore, separating neuropsychiatric conditions
into neurological and mental health conditions revealed dispro-
portionately low funding in mental health compared with the re-
lated disease burden [14]. This corroborates concerns over a lack of
investment in dementia research and services [15–17]. Only Lich-
tenberg [18] used output measures of innovation and found a pos-
tive relationship among developed countries. This was based pri-
arily on pharmaceuticals launched; drugs currently on sale and
elevant published articles were used as innovation outcomes in
dditional analyses, but these were limited to the United States
nd cancer, respectively.
Horizon scanning or early awareness and alert systems have
een implemented in many developed countries to identify new
nd emerging health technologies, with the aim ofmanaging their
ntroduction into resource-limited health-care systems. One facet
f their work is to anticipate technologies that will have a signifi-
ant, positive impact on patients and systems, and those with
anning Centre, University of Birmingham, 90 Vincent Drive, Edg-
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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377V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 3 7 6 – 3 8 0potentially negative impacts. The results of horizon scanning ac-
tivity may be considered an ideal proxy measure for innovation,
because it attempts to capture all important new interventions
and products relevant to health-care services. This study exam-
ines the relationship between disease burden and the reporting of
health innovations among the 20 member agencies of EuroScan
(the International Information Network on New and Emerging
Health Technologies) [19]. We compare health technologies re-
orted by EuroScan from 2000 to 2009 with burden of disease
World Health Organization [WHO]:WHO 2004 estimates) [2] in the
17 developed countries represented, at different levels of disaggre-
gation.
Methods
Innovation: Horizon scanning output
Horizon scanning output was measured as the number of unique
technologies uploaded onto the EuroScan database between 2000
and 2009, both inclusive. EuroScan member agencies are all non-
commercial, nonprofit organizations operating in relation to re-
gional or national government, representing the following coun-
tries: Australia, Austria, Canada, Denmark, England, Finland,
France, Germany, Ireland, Israel, Italy, the Netherlands, New Zea-
land, Norway, Spain (incorporating autonomous regional early
awareness and alert systems in Andalucía and the Basque Coun-
try), Sweden, and Switzerland (see http://www.euroscan.org.uk).
Technologies include drugs, devices, diagnostics, interventions
(e.g., surgery), programs (e.g., screening programs), and organiza-
tional changes to the delivery of health care (e.g., delivery in dif-
ferent settings) [19].
Burden of disease
Burden of disease was measured as disability-adjusted life-years
(DALYs) and deaths for 2004 for countries within EuroScan (up-
dated WHO Global Burden of Disease estimates) [2]. The 2004 es-
timates were the most up-to-date available. These were summed
to generate composite DALYs and deaths for countries repre-
sentedwithin EuroScan. Bivariate Pearson’s correlationswere per-
formed to determine the extent to which DALYs for specific dis-
eases (N 102; see “Classification of Diseases” section below)were
orrelated between countries. This was repeated for deaths. A
igh degree of linear association between all countries for both
ALYs and deaths indicated similar distributions of disease bur-
en (DALYs: r  0.8, N  102, P  0.001; deaths: r  0.8, N  102,
P  0.001 for all comparisons).
Classification of diseases
Diseases (or causes) are grouped in the first three levels of the
four-stage hierarchy used in the WHO Global Burden of Disease
studies [1,2]. At the first level, there are three main categories:
communicable, maternal, perinatal, and nutritional conditions;
noncommunicable diseases; and injuries. At the second level,
Table 1 – Reported technologies, DALYs, and deaths for lev
Level 1 group
I: Communicable, maternal, perinatal, and nutritional conditions
II: Noncommunicable diseases
III: Injuries
Total
DALYs, disability-adjusted life-years.these categories are broken down into 21 disease groups; for ex-ample, “noncommunicable diseases” consists of 14 groups, in-
cluding malignant neoplasms and diabetes mellitus. At the third
level, some of these groups are broken down further into specific
diseases; for example, “malignant neoplasms” consists of 17 spe-
cific types of cancer. This level also includes “other” categories
(e.g., “othermalignant neoplasms” includes less common forms of
cancer, such as sarcoma and glioma). There are 102 specific dis-
eases at the third level. We created an additional third-level cate-
gory for “all malignant neoplasms” to take into account technolo-
gies that covered multiple types of cancer or were nonspecific.
This category is included within the broader “malignant neo-
plasms” group for analysis at the second level, but not otherwise at
the third level.
Assigning disease classification to reported technologies
Of all the technologies uploaded onto the EuroScan database
between 2000 and 2009, 45% were drugs, 23% devices, 14% pro-
cedures, 12% diagnostics, 3% programs, and 1% settings. The
remainder were unspecified. We assigned disease classification
codes to technologies in stages. At the first stage, we assigned
codes to all entries with an indication clearly specified within
the title (e.g., “vaccine for herpes zoster”). Approximately 70% of
technologies were coded in this way. At the second stage, we
scrutinized the full database records for entries without a clear
indication in the title and extracted the information where pos-
sible. Technologies that could not be coded included those with
vague or very broad indications (e.g., “cancer”), those with no
specific indication, and those whose indications could not be
linked to specific diseases (e.g., contraception, smoking cessa-
tion, and general wound care). Coding did not discriminate be-
tween different stages of the same disease; for example, a drug
for metastatic melanoma indicated for both stages III and IV
disease would be coded only once as melanoma. Technologies
with more than one indication received separate codes for each
disease.
Statistical analysis
Theassociationbetweenhorizon scanningoutput andburdenof dis-
ease (DALYs and deaths) was analyzed by using bivariate Pearson’s
correlations in SPSS Statistics 17.0 (IBM, New York, USA). Fisher’s z
transformation was used to calculate 95% confidence intervals for
each value of r. The analysiswas repeated for both broader disease
groups (level 2) and specific diseases (level 3).
Results
Of 1451 unique technologies entered on the EuroScan database
between 2000 and 2009, 80 (5.5%) could not be coded and were
therefore excluded from the analysis. This left 1371 unique
technologies with 1479 individual indications. At the first level,
noncommunicable diseases accounted for approximately 90%
of technologies, DALYs, and deaths (Table 1).
At the second level, three disease groups predominated (Fig. 1).
categories.
eported technologies, n(%) DALYs
(’000s)
Deaths
(’000s)
102 (6.9) 2346 (4.6) 196 (5.0)
1367 (92.4) 45,051 (88.1) 3460 (89.9)
10 (0.7) 3712 (7.3) 191 (5.0)
1479 (100) 51,109 (100) 3847 (100)el 1
RNeuropsychiatric conditions had the most DALYs but dispropor-
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378 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 3 7 6 – 3 8 0tionately fewer technologies, and malignant neoplasms had the
highest number of technologies but disproportionately fewer
DALYs. Cardiovascular disease accounted for high numbers of
both DALYs and technologies. There was a moderate positive cor-
relation between DALYs and reported technologies (r 0.72, n 21,
 0.001, 95%CI 0.42–0.88), but thiswasprincipally due to the outlier
ffect of the three key groups. Excludingmalignant neoplasms, neu-
opsychiatric conditions, and cardiovascular disease from the anal-
sis greatly weakened the association among the remaining disease
roups (r  0.37, n  18, P  0.05, 95% CI 0.12 to 0.72). At the third
Fig. 1 – Correlation between DALYs and technologies for
level 2 disease groups. DALYs, disability-adjusted life-
years.Fig. 2 – Correlation between DALYs and technologies forevel of disease disaggregation, the association between DALYs and
echnologies was weaker (Fig. 2; r  0.48, N  102, P  0.001, 95% CI
.31–0.62) than at the second level. Diseases within malignant neo-
lasms consistently had a greater number of technologies than ex-
ected based on DALYs, with “other” malignant neoplasms and
reast cancer having the greatest discrepancies. Diseases within
europsychiatric conditions generally had lower technology num-
ers than expected, with the exception of “other” neuropsychiatric
onditions. Diseases within cardiovascular disease were more
idely scattered,with “other” cardiovasculardiseases representinga
isproportionately high number of technologies. Using mortality
ather than DALYs did not greatly alter the results, either at the sec-
nd level of classification (r 0.84, n 21, P 0.001, 95%CI 0.64–0.93)
r at the third level (r 0.60, N 102, P 0.01, 95% CI 0.45–0.71).
Highest-ranking causes for reported technologies with corre-
sponding DALY and death rankings are shown in Table 2. Of the 30
diseases accounting for the highest numbers of reported technolo-
gies, 13 were among the leading DALY causes and 14 among the
leading death causes. “Other” cardiovascular diseases had the high-
est number of technologies, followed by “other” malignant neo-
plasms. Unipolar depressive disorder had the highest number of
DALYs and a relatively low number of technologies. Ischemic heart
disease represented the highest number of deaths and was the sec-
ond highest ranking DALY cause, but had proportionately fewer
technologies.
Discussion
Overall we have found at best a weak level of association between
innovation and burden of disease. Although the results for a high
level of disease aggregation suggest an association, it is dependent
on three high-prevalence disease groups: cancers, neuropsychiat-
ric conditions, and cardiovascular disease. The results do not sup-
Diseaselevel 3 causes. DALYs, disability-adjusted life-years.
379V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 3 7 6 – 3 8 0port previous reports of a positive relationship between burden of
disease and innovation [18] but are consistent with evidence of
notable discrepancies among key disease groups [9]. Our results
are based on existing horizon scanning systems and so cannot be
generalized to developing countries, most of which do not have
such systems in place. Others, however, have reported a weaker
innovation (and R&D) association with need in developing coun-
tries [6–8,18,20,21].
Although our findings are at some odds with previous reports,
our study has a number of advantages, albeit with caveats. This is
the first study to use horizon scanning output to measure innova-
tion in addressing burden of disease. Unlike research using fund-
ing as an indicator of innovation [8,9], we use a measure of output
rather than intention to address burden of disease. The data come
from 10 years of scanning by an international network of horizon
scanning systems. The caveat is that there is heterogeneity be-
tween agencies in practice and activity levels [22,23]. Although
most agencies cover all diseases, differences in policy and practice
mean that the technologies they report may not represent these
areas equally, and although arguably the differences balance out it
must nevertheless be acknowledged that early awareness and
alert activity is an imperfect proxy for innovation. It does not rep-
resent all innovations, but only those that have reached a rela-
tively advanced stage of development and are important to the
health-care systems supporting this activity. Precision of report-
ing also varies between agencies: for example, one might report a
drug’s indication as metastatic breast cancer, whereas another
might simply state “breast cancer,” although this is not a concern
here as the WHO data were grouped only as finely as individual
Table 2 – Highest ranking causes for reported technologies
Technologies Numb
techno
Other cardiovascular diseases 15
Other malignant neoplasms 8
Endocrine disorders 7
Other musculoskeletal disorders 6
Diabetes mellitus 5
Breast cancer 5
Ischemic heart disease 5
Other digestive diseases 5
Other neuropsychiatric disorders 5
Colon and rectum cancers 4
Trachea, bronchus, lung cancers 4
Prostate cancer 3
Macular degeneration and other sense organ diseases 3
Other genitourinary system diseases 3
Skin diseases 3
Lymphomas, multiple myeloma 2
Cerebrovascular disease 2
Leukemia 2
Other neoplasms 2
Other infectious diseases 2
Congenital anomalies 2
Melanoma and other skin cancers 2
Unipolar depressive disorders 2
Nephritis and nephrosis 2
Rheumatoid arthritis 2
Asthma 1
Osteoarthritis 1
Hypertensive heart disease 1
Alzheimer and other dementias 1
Other respiratory diseases 1
DALYs, disability-adjusted life-years.diseases, and not their different types or stages. The WHO DALYmethodology is widely accepted, and our DALY association find-
ings are supported by our findings formortality data alone [2]. One
concernwith using DALYs for international comparisons is whether
the disability weights assigned to each disease have cross-national
stability; however, research across developed countries has sup-
ported the assumption of universality [24–27].
While disease classification can be problematic, we have delib-
erately explored its effect. On the one hand, the coarseness of the
classification can contribute to the instability of the association;
on the other hand, there is a level of disaggregation where a cor-
relationwith the relative rarity of innovationwould be impossible,
but we do not think that that is an issue with the levels of aggre-
gation that we have explored.
To an extent the results accord the current health service and
patient emphasis on cancer. Yet they are also consistent with con-
cerns that neuropsychiatric conditions, particularly dementia, are
underfunded [15–17]. Dementia has been identified as an R&D pri-
ority [11,12], and our findings imply that this is not happening, or
at least not leading to final outputs. Two comments are worth
noting: first, factors other than absolute disease burden drive
innovation. Relatively little is still known about the causes of
physiological changes leading to dementia [28], and so the de-
velopment of disease-modifying therapies will be slower than
for conditions where the disease pathophysiology is better es-
tablished. The high number of cancer technologies suggests an
increase in industry breakthroughs in a prominent market.
Moreover, the number of new technologies is not necessarily
representative of the degree of innovation; for example, one
blockbuster drug may have a greater impact on treatment out-
el 3), with associated DALY and death rankings.
s
Rank DALYs
(’000s)
Rank Deaths
(’000s)
Rank
1 1800 6 386.4 2
2 1307 11 141.9 5
3 772 21 31.6 32
4 616 29 17.4 39
5 1378 10 101.4 11
6 953 17 91.6 12
6 3436 2 644.4 1
6 1271 12 109.0 10
9 893 19 32.1 31
10 1032 15 140.3 6
10 1680 8 214.4 4
12 386 37 70.8 13
13 624 28 0.1 80
13 134 68 21.8 37
15 90 75 8.3 47
16 430 34 58.7 16
16 1916 4 357.1 3
18 315 42 39.4 24
19 189 59 33.6 28
20 276 45 33.3 30
21 593 31 12.1 42
22 171 62 18.7 38
22 4008 1 2.0 66
22 191 58 46.1 21
22 435 33 3.8 60
26 741 24 8.6 46
26 1223 13 1.7 67
28 293 44 68.4 15
29 2134 3 134.4 7
29 753 22 69.7 14(lev
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5comes than do several modifications of existing therapies. Sec-
[380 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 3 7 6 – 3 8 0ondly, the focus of activity among EuroScan agencies tends to
be tangible innovations, that is, drugs, devices, and diagnostics
rather than programs and prevention, which may be more ap-
propriate for treating and managing neuropsychiatric condi-
tions. The fact that the agencies introducing the vast majority of
technologies focus predominantly on drugs [23], whichmake up
a large number of cancer therapies, may also contribute to the
high number of technologies in this area. A final issue is
whether the burden of disease as measured by DALYs best re-
flects the need for innovation. While DALYs incorporate both
disease severity and the numbers affected, they may not mirror
a societal preference for giving priority to some rare conditions.
But that is a different issue from that addressed in this article.
Finally, it is important to take context into account when eval-
uating investment decisions relating to R&D in health care. The
relative paucity of tangible innovation does not necessarily mean
a reduced focus of concern in low innovation areas. However, the
question of how that concern be addressed in the absence of in-
novation, whether by stimulating innovation or by compensating
for its absence in other ways, is wide open.
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